Suppr超能文献

肾小球疾病的细胞毒性治疗。五、环磷酰胺联合泼尼松、硫唑嘌呤联合泼尼松及环磷酰胺单药治疗肾小球肾炎的比较研究。哥本哈根肾脏疾病研究小组报告

Cytostatic treatment of glomerular diseases. V. Treatment of glomerulonephritis with cyclophosphamide plus prednisone, azathioprine plus prednisone and cyclophosphamide as monotherapy. A comparative study. A report from a Copenhagen Study Group of Renal Diseases.

作者信息

Brahm M, Balsløv J T, Brammer M, Brun C, Gerstoft J, Jørgensen H E, Kamper A, Larsen S, Lorenzen I, Thomsen A C

机构信息

Department of Nephrology, Herlev Hospital, Copenhagen, Denmark.

出版信息

Acta Med Scand. 1988;224(6):605-10.

PMID:3061292
Abstract

Thirty-two patients suffering from biopsy-proven glomerulonephritis with proteinuria greater than or equal to 1.2 g/24 hours and/or creatinine clearance less than 50% of normal value were treated for 6 weeks with prednisone plus cyclophosphamide (C+P), azathioprine (A+P) or cyclophosphamide as a monotherapy (C). The effect of the treatment was evaluated after 6 and 16 weeks. The results were entered consecutively in a sequential analysis. The three treatment regimes were compared mutually as well as with the results of 16 weeks' treatment with C and placebo, published previously. Six weeks' treatment with C+P or A+P was superior to C and at least as efficient as 16 weeks' C treatment. C treatment for 6 weeks was less efficient than 16 weeks' C treatment. The side-effects of the 6 weeks' A+P or C+P treatment were fewer and less serious than those reported from the long-term C treatment.

摘要

32例经活检证实为肾小球肾炎、蛋白尿大于或等于1.2g/24小时和/或肌酐清除率低于正常值50%的患者,接受了泼尼松联合环磷酰胺(C+P)、硫唑嘌呤(A+P)治疗6周,或环磷酰胺单一疗法(C)。在治疗6周和16周后评估治疗效果。结果连续纳入序贯分析。将三种治疗方案相互比较,并与先前发表的C和安慰剂治疗16周的结果进行比较。C+P或A+P治疗6周优于C,且至少与C治疗16周的疗效相同。C治疗6周的疗效低于C治疗16周。A+P或C+P治疗6周的副作用比长期C治疗报告的副作用更少、更轻。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验